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Systemic administration of α2-adrenergic agonists has been shown to protect 
ischemic myocardium, but the direct effects on ischemia-reperfused myocardium have 
not yet been clarified.  This study was carried out to determine the effects of 
intracoronary dexmedetomidine (DEX) on the myocardial ischemia-reperfusion injury 
in anesthetized pigs.  In open-chest pigs, the left anterior descending coronary artery 
(LAD) was perfused through an extracorporeal circuit from the carotid artery.  They 
received intracoronary infusion of DEX at a rate of 1 ng/mL (group LD, n = 9), 10 
ng/mL (group MD, n = 9), or 100 ng/mL (group HD, n = 9) of coronary blood flow or 
vehicle (group C, n = 12) for 30 min before ischemia.  Myocardial stunning was 
produced by 12-min ischemia of the perfused area of LAD and 90-min reperfusion.  
The effect on reperfusion-induced arrhythmias was evaluated using the incidence of 
ventricular tachycardia or fibrillation after reperfusion.  Regional myocardial 
contractility was evaluated with segment shortening (%SS).  DEX significantly 
reduced the incidence of reperfusion-induced ventricular arrhythmias.  DEX 
significantly improved the recovery of %SS at 90 min after reperfusion (32.6 ± 3.1% in 
group C, 58.2 ± 2.1% in group LD, 61.1 ± 1.8% in group MD and 72.0 ± 2.0% in group 
HD.  DEX suppressed the increase of plasma norepinephrine concentration after 
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reperfusion.  The results indicate that DEX would exert the protective effect against 
ischemia-reperfusion injury by the direct action on the myocardium, which is not 
mediated through central nervous system.  
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The progression of interventional recanalization for the treatment of acute 
coronary syndrome has been shown to reliably improve prognosis, on the other hand, it 
has been shown that the reperfusion itself causes a serious phenomenon termed 
reperfusion injury in clinical settings (1).  Brief periods of coronary artery occlusion 
followed by reperfusion produces reversible contractile dysfunction, i.e., stunning, for 
several hours and are associated at the time of reflow with lethal arrhythmias, 
ventricular tachycardia (VT) or fibrillation (VF) (2, 3).  Elimination of reperfusion 
injury may further improve the outcome of patients with coronary artery disease (1).   
Experimental and clinical studies suggest that catecholamines promote the 
progression of myocardial injury, and arrhythmogenic effects of enhanced sympathetic 
activity and cardiac catecholamine concentrations are well documented (4).  Previous 
studies reported that myocardial ischemia rapidly and massively increased the 
norepinephrine (NE) concentration in the myocardial tissue, but not in systemic blood 
sample (5, 6).  Miura et al. (6) also reported that the elevation of NE concentration 
during ischemia was markedly attenuated by ischemic preconditioning. 
α2-Adrenergic agonists have been reported to have protective effects on the 
ischemic myocardium such as coronary artery stenosis or myocardial stunning, and 
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attenuate plasma NE levels, and preserve myocardial blood flow in the inner layers in 
the laboratory (7-9).  It is well known that the central sympatholytic effect of 
α2-adrenergic agonists may be beneficial during myocardial ischemia.  
α2-Adrenoreceptors also exist at sympathetic nerve endings, and cardiac presynaptic 
α2-adrenoreceptor stimulation decreased NE release from sympathetic nerve endings 
(10).  Thus, cardiac presynaptic α2-adrenoreceptor stimulation would attenuate the 
elevation of NE concentration in ischemic myocardium.  However, the effects of 
cardiac presynaptic α2-adrenoreceptor stimulation on ischemia-reperfused myocardium 
have not yet been clarified.  
 Dexmedetomidine (DEX) is a highly specific and selective α2-adrenergic 
agonist.  α2-Adrenergic agonists are useful adjuncts to anesthesia because of their 
sedative, analgesic, sympatholytic, and specific hemodynamic effects (11).  It has been 
shown that DEX was associated with a trend towards improved cardiac outcomes in a 
clinical setting (12).  The aims of this study were to determine whether DEX could 
exert direct protective effects against myocardial stunning and reperfusion-induced 
ventricular arrhythmias, and to investigate the influence on the myocardial NE 
concentration in anesthetized pigs. 
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Materials and Methods 
 All experimental procedures used in this investigation were reviewed and approved 
by the Animal Care Committee of the Nagasaki University School of Medicine.   
 
Instrumentation 
 Thirty-nine pigs (20–35 kg) of either sex were sedated with ketamine 
hydrochloride (20 mg/kg) intramuscularly.  After intravenous (IV) access was 
established via an ear vein, the pigs were anesthetized with α–chloralose (100 mg/kg) 
and fentanyl (10 µg/kg) IV, followed by continuous infusion of α–chloralose (10 
mg/kg/h) and fentanyl (5 µg/kg/h) throughout the study period.  Through a midline 
cervical incision, the trachea was intubated for connection to a Harvard respiratory 
pump (Harvard Apparatus Co., South Natick, MA).  Mechanical ventilation was 
facilitated by an intermittent IV infusion of vecuronium (0.2 mg/kg).  Tidal volume, 
respiratory rate, and inspired oxygen concentration were adjusted to maintain the 
arterial carbon dioxide tension (PaCO2) between 35 and 40 mmHg, and the arterial 
oxygen tension (PaO2) between 100 and 300 mmHg.  End-tidal CO2 concentration was 
continuously monitored by using a gas analyzer (Capnomac Ultima, Datex, Helsinki, 
Finland).  Lactated Ringer’s solution was infused at a rate of 5 ml/kg/h.  Sodium 
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bicarbonate was administered to maintain the base deficit within 5 mEq/L.  Arterial 
blood glucose concentrations were measured before and during ischemia and 
maintained at baseline values with an IV infusion of 10% dextrose as needed throughout 
the study period.  The esophageal temperature was maintained between 36°C and 37°C 
throughout the study period by using a warmer blanket and a heating lamp. 
 A heparin-filled catheter was inserted into the right carotid vein to administer fluid 
and drugs.  A standard peripheral lead electrocardiogram was monitored continuously.  
A medial sternotomy was performed and the pericardium opened, exposing the heart.  
Systemic anticoagulation was achieved with sodium heparin (750 U/kg) IV, followed by 
continuous infusion of sodium heparin (250 U/kg/h).  The left anterior descending 
coronary artery (LAD) distal to the first diagonal branch was cannulated with a 
stainless-steel cannula and perfused with blood from the left carotid artery through an 
extracorporeal circuit.  Coronary perfusion pressure (CPP) was measured from the 
sidearm of the circuit, using pressure transducer-tipped catheter (PC500; Millar 
Instruments), and coronary blood flow (CBF) of the perfused area of LAD was 
measured with an ultrasonic flow probe (ADP17; Crystal Biotech, Hopkinton, MA) 
attached at the circuit.  The circuit also contained a distal infusion port for drug 
administration.  A 22-gauge catheter was inserted into epicardial vein at the same level 
9 
 
as was LAD to allow coronary venous blood sampling.  The venous cannula was 
allowed to drain freely into a beaker to prevent venous stagnation.  This venous blood 
was returned intermittently to the pig to maintain isovolemic conditions.  A pressure 
transducer-tipped catheter (PC500; Millar Instruments) was inserted into left ventricular 
(LV) chamber through an incision in the apex for continuous recording of LV pressure 
(LVP).  The peak rate of increase in LVP (LVdP/dtmax) was determined by electric 
differentiation of the LV pressure waveform.  A pair of ultrasonic segment length 
transducers was implanted in the subendocardium of the perfused area of LAD to 
measure changes in regional contractile function (percentage segment shortening 
[%SS]).  Segment length was monitored by ultrasonic amplifiers (VF-1; Crystal 
Biotech).  End-systolic segment length (ESL) was determined 10 ms before maximum 
negative LVdP/dt, and end-diastolic segment length (EDL) was determined 10 ms 
before dP/dt first exceeded 140 mmHg•s-1 (immediately before the onset of LV 
isovolemic contraction).  %SS was calculated using the formula; %SS = (EDL – ESL) 
× 100 × EDL–1.  All hemodynamic data were continuously monitored on a polygraph 
and digitized via a computer interfaced with an analog-to-digital converter (HEM; 




Assay of plasma NE concentrations 
 Assay of plasma NE concentrations in coronary venous blood samples of the 
perfused area of LAD was undertaken at baseline and immediately after reperfusion, 
and determined by high-performance liquid chromatography with coulometric 
electrochemical detection.   
 
Measurement of regional myocardial blood flow (RMBF) 
 Colored microspheres (Dye-trak; Triton Technology Inc., San Diego, CA) used to 
measure RMBF were injected into the extracorporeal circuit at baseline and before 
ischemia.  Immediately before injection, the microspheres were suspended using 
Voltecs® (Scientific Industries, Bohemia, NY).  Microspheres (15 µm in diameter) 
were injected into the extracorporeal circuit as a bolus during a 30-s period.  Two 
milliliters of methylene blue was injected into the circuit, and the dyed area was 
resected as the perfused area after cardiac arrest with KCl injection.  After the weight 
of the resected tissue was measured, the tissue was isolated and divided into four 
transmural sections, which were subsequently subdivided into inner, middle, and outer 
layers.  After being weighed, each piece and the remaining myocardial tissue of the 
dyed region were separately dissolved by 4 mol•l-1 KOH, and colored microspheres 
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were collected by vacuum filtering.  These microspheres were dissolved by 
dimethylformamide, and the photometric absorption of each dye solution was 
determined by an UV-visible recording spectrophotometer (UV-160A; Shimazu Co., 
Kyoto, Japan). 
 The composite spectrum of each dye solution was resolved into the spectra of the 
single constituent by a matrix-inversion technique incorporated into the 
spectrophotometer.  By using calculated photometric absorption, RMBF was 
determined by using the equation; Qm = (Am × Qt) / At, where Qm is blood flow of 
samples (mL/min/g), Qt is total CBF (mL/min), Am is photometric absorption in sample, 
1 g, and At is total photometric absorption of the perfused area of LAD. 
 
Experimental protocols 
 Figure 1 shows the experimental design.  Thirty minutes after the instrumentation 
was completed, baseline systemic and coronary hemodynamics were recorded.  Pigs 
were randomly assigned to one of four groups.  If the pig was excluded before 
completion of the experiment, the next one was assigned to the same group.  Each 
group received intracoronary infusion of DEX at a rate of 1 (group LD, n=9) or 10 
(group MD, n=9) or 100 (group HD, n=9) ng/mL of CBF or drug vehicle (group C, 
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n=12) for 30 min before ischemia.  Coronary blood concentration (ng/mL) of DEX 
was calculated by dividing the intracoronary infusion rate (ng/min) by the prevailing 
CBF rate (mL/min).  The concentrations of low-dose DEX corresponded to clinical 
plasma concentrations for sedation in the intensive care (13).  DEX was diluted with 
saline, and infused at a rate of 1.0-2.0 mL/min.  All pigs were subjected to 12-min 
ischemic period followed by a 90-min reperfusion.  The ischemia was produced by the 
complete occlusion of the extracorporeal circuit.  The hemodynamics and the 
contractile function were monitored continuously throughout the experiment.  In large 
mammals, dogs, and pigs, myocardial stunning can be induced by a single completely 
reversible episode of regional ischemia lasting less than 20 min.  We carried out 
preliminary study to determine the ischemic period.  We aimed at about 50% recovery 
from baseline after 90-min reperfusion.   
 If more than five premature ventricular contractions (PVC) per minute or 
multifocal PVC occurred, lidocaine (1mg/kg IV) was administered.  This was repeated 
if necessary.  VT and VF were treated with lidocaine (1 mg/kg IV) followed by direct 
defibrillation of the heart with 40 joules.  If the animal did not recover from VT or VF 
after direct defibrillation once, the case was considered intractable and excluded from 
the study.  Exsanguination was carried out by opening extracorporeal circuit under 
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anesthesia.  The effect on reperfusion-induced arrhythmias was evaluated with the 




 All data are expressed as mean ± SEM.  One-way analysis of variance 
(ANOVA) for non-repeated measures followed by the Bonferroni’s post hoc test was 
used to test for differences in baseline hemodynamics and %SS.  Data within groups 
were analyzed with one-way ANOVA for repeated measures, and data between groups 
were analyzed with two-way repeated measures ANOVA followed by the Bonferroni’s 
post hoc test.  Incidences of VT or VF were compared using Fischer’s exact test.  P 
values <0.05 were considered statistically significant.  Statistical analysis was 
performed using SPSS 15.0 software (SPSS Japan, Tokyo, Japan) 
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3. Results  
 There were no significant differences in demographic data among groups.  
Arterial blood gas values and blood glucose were maintained within physiologic range 
in all pigs.   
 
Reperfusion-induced arrhythmias 
 Assessments of reperfusion-induced arrhythmias are summarized in Table 1.  
Eight pigs (67%) in group C, two pigs (22%) in group LD, and one pig (11%) in groups 
MD and HD exhibited VT or VF, and were treated with direct defibrillation.  Four in 
group C, and one in groups LD and MD did not recover from VT or VF after direct 
defibrillation once; these cases were considered intractable and excluded from the study.  
The incidences of reperfusion-induced VT or VF in groups MD and HD were 
significantly lower than that in group C.  Moreover, the DEX groups required less 
lidocaine than group C.  
 
Hemodynamics 
 Changes of hemodynamics and %SS are summarized in Table 2.  There were no 
significant differences in the systemic and coronary hemodynamics or %SS between 
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pre- and post-treatment of DEX (1 ng/mL or 10 ng/mL or 100 ng/mL).  LVdP/dtmax 
were reduced significantly during ischemia and remained depressed throughout 
reperfusion in all groups.  LVEDP increased significantly during ischemia and early 
reperfusion but returned to baseline values at 90 min after reperfusion in all groups.  
CBF significantly increased 5 min after reperfusion compared with the baseline values 
in all groups.  
 
Dex improves myocardial stunning 
 Figure 2 shows the percentage changes of %SS from baseline (100 %) throughout 
the time course.  In all groups, %SS markedly decreased and fell below 0% during 
ischemia, indicating bulging.  The group C showed poor recovery of %SS during 
reperfusion, which was no more than 35% of baseline even after 90 min.  All-dose 
DEX significantly enhanced the functional recovery from myocardial stunning 
compared with controls.  Moreover, high-dose DEX significantly improved the 
functional recovery (72% of baseline at 90 min after reperfusion) compared with 
medium-dose (61% of baseline) and low-dose (58% of baseline) DEX. 
 
Dex reduces plasma NE concentrations 
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 Figure 3 presents the plasma NE concentrations in coronary venous blood 
sampling of the perfused area of LAD.  In the group C, the NE concentrations 
significantly increased after reperfusion compared with the baseline.  DEX 
significantly suppressed the increases of the NE concentrations after reperfusion.   
 
Dex and RMBF 
 Figure 4 presents the subendocardial to subepicardial (endo/epi) blood flow 
ratio.  In the group C, LD and MD, this ratio did not significantly change after the 
administration of the drug compared with the baseline.  In contrast, high-dose DEX 




 The present results show that intracoronary infusion of DEX significantly improves 
regional myocardial contractility after 12-min ischemia and reperfusion of the perfused 
area of LAD in a dose-dependent manner, and suppresses reperfusion-induced 
ventricular arrhythmias in anesthetized pigs.  These results suggest that DEX has direct 
protective effects against myocardial ischemia-reperfusion injury.  In addition, DEX 
suppresses an increase in the plasma NE concentrations after reperfusion and increases 
the endo/epi blood flow ratio.   
 Myocardial reperfusion injury has four basic forms; lethal myocyte injury, vascular 
injury, stunned myocardium and reperfusion arrhythmias (1).  Stunned myocardium 
and reperfusion arrhythmias are produced by brief periods (< 20 min) of coronary artery 
occlusion followed by reperfusion and are reversible injury in experimental studies (3, 
14).  Lombardi et al. (15) showed that a brief period of LAD occlusion followed by 
reperfusion caused sympathetic activation and a decrease in the VF threshold in dogs.  
Shindo et al. (16, 17) reported that both a short period (10 min) and a prolonged period 
(40 min) of coronary artery occlusion increased myocardial interstitial NE level in the 
ischemic region in cats.  Chen et al. (18) showed that postischemic heart had a large 
amount of coronary NE overflow in an isolated working heart preparation.  It is 
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considered that mechanism of stunned myocardium and reperfusion arrhythmias is 
associated with the increase of extracellular NE concentration within the ischemic 
myocardium irrespective of central sympathetic activity.   
 Several studies reported that intravenous administration of clonidine, an 
α2-adrenergic agonist, and DEX could prevent a myocardial ischemia-induced NE 
release in anesthetized dogs (9, 19, 20).  Mivazerol, α2-adrenergic agonist, also 
suppressed the increase of plasma NE concentration and preserved myocardial blood 
flow in the inner layers during coronary artery stenosis in anesthetized dogs (10).  
Meissner et al. (9) showed that clonidine improved recovery from myocardial stunning 
and attenuated increases in catecholamine plasma levels in dogs.  Thus it is considered 
that α2-adrenergic agonists exert myocardial protection resulting from the attenuation of 
the catecholamine response to ischemic stress and redistributing myocardial blood flow.  
However, these protective effects might depend on central nervous actions by systemic 
administration of α2-adrenergic agonists.  In the present study, intracoronary DEX 
administration suppressed an increase in NE release in the coronary venous blood 
sampling of the ischemic region, and exerted protective effects against reperfusion 
injury.  Cai et al. (21) reported that α2-adrenergic receptors were present in the heart in 
vitro, and α2-adrenergic stimulation prevented reperfusion-induced VT/VF in vivo and 
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that this effect is not centrally mediated.  The release of NE from the isolated human 
papillary muscle was inhibited by xylazine, an α2-adrenergic agonist (10).  Thus, the 
cardioprotective effects of intracoronary DEX administration should be mediated 
through cardiac presynaptic α2-adrenoreceptor stimulation.  
 The direct effects of α2-adrenergic agonists on coronary vasculature are 
controversial.  Heusch et al. (22) showed that activation of coronary vascular 
α2-adrenergic receptors induced poststenotic coronary vasoconstriction and myocardial 
ischemia.  However, previous studies indicated that α2-adrenergic coronary 
vasoconstriction exerts a favorable effect on ischemic myocardium preventing a 
transmural redistribution of blood flow away from the endocardium and improving 
endo/epi blood flow ratio (23, 24).  Moreover, Kitakaze et al. (25) demonstrated that 
intracoronary α2-adrenergic stimulation increased CBF during ischemia by enhancing 
the vasodilative effects of adenosine released from the ischemic myocardium.  In 
non-ischemic heart, systemic administration of DEX induced a pronounced decrease in 
CBF in dogs (26).  However, Meissner et al. (9) reported that clonidine increased 
endo/epi blood flow ratio in normal condition.  In the present study, CBF was not 
changed after intracoronary DEX administration, but in the group HD endo/epi blood 
flow ratio was significantly increased in normal condition.  Lawrence et al. (27) also 
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reported that DEX at 10 µg/kg but not 0.1 or 1 µg/kg increased endo/epi blood flow 
ratio without changing CBF in halothane- and fentanyl-anesthetized dogs.  This effect 
of high-dose DEX may cause more improvement of the functional recovery from 
myocardial stunning.     
 The application of cardioprotective therapy after reperfusion is clinically 
feasible because the onset of reperfusion is predictable and is under the clinician’s 
control.  The present results show that intracoronary infusion of DEX before ischemia 
enhanced the functional recovery of stunned myocardium and suppressed 
reperfusion-induced ventricular arrhythmias.  Okada et al. (28) reported that 
administration of DEX during the pre-ischemic period reduces myocardial infarct size 
in isolated rat heart.  On the other hand, Guo et al. (29) reported that administration of 
DEX pre-hypoxia, but not post-hypoxia, exerts a direct protective effect on the left 
ventricular dysfunction caused by hypoxia-reoxygenation in isolated rat heart.  
Mimuro et al. (30) also demonstrated that administration of DEX after reperfusion did 
not influence hemodynamics or CBF, but increased myocardial infarct size in isolated 
rat heart.  The mechanisms of this discrepancy are not known; however, administration 
of DEX after reperfusion might not be beneficial or deleterious.   
The doses of DEX using in this study were set on the basis of a previous study 
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using 0.7–14.7 ng/ml DEX in volunteers (31), and the concentrations of DEX in groups 
LD and MD corresponded to 10 and 100 times clinical plasma concentrations for 
sedation in intensive care (13).  It is possible that a factor other than α2-adrenergic 
agonist activity affected the present results in group HD.  The present results show that 
high-dose DEX significantly increased endo/epi blood flow ratio and caused greater 
improvement in terms of functional recovery.  In addition, we suggest that the greater 
improvement in terms of functional recovery is mediated by an increase in endo/epi 
blood flow ratio.  These results are consistent with previous studies using other 
α2-adrenergic agonists, such as mivazerol or clonidine (8, 9).  It is likely that the 
effects of a factor other than α2-adrenergic agonist activity are only small, even with the 
use of high-dose DEX in this study.  The esophageal temperature (36-37°C) 
maintained in this study was slightly lower than the normal temperature.  Hypothermia 
would affect myocardial injury (32).  However, mild hypothermia is thought to occur 
below 35°C, and there were no significant differences in terms of esophageal 
temperature among the groups in this study.  The body temperature should not have 
affected our results. 
 In the present study, while the LAD was perfused with blood containing DEX, 
venous effluent containing DEX (that portion not collected via the implanted coronary 
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venous catheter) returned directly to the systemic circulation.  However, this venous 
return is the relatively small size compared to the total systemic venous return.  In 
addition, systemic hemodynamic parameters did not vary during the intracoronary 
infusion of DEX.  Therefore, although measurements of aortic blood concentrations 
were not available to confirm, we assumed that its concentrations in the systemic 
arterial circulation remained low and did not exert central nervous actions.   
 In conclusion, intracoronary DEX enhanced the functional recovery of stunned 
myocardium and suppressed reperfusion-induced ventricular arrhythmias.  These 
effects are possible due to preventing an increase of myocardial NE level in ischemic 
region through cardiac presynaptic α2-adrenoreceptor stimulation, but this is not 
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Figure legends  
Figure 1: Time course of the experimental protocol.   
All pigs were subjected to 12-min ischemia of the perfused area of left anterior 
descending coronary artery (LAD) and subsequent 90-min reperfusion.  Drug vehicle 
and dexmedetomidine (DEX) were administered by an intracoronary infusion for 30 
min before ischemia.  During experiment, hemodynamics, percentage of segment 
shortening (%SS), plasma norepinephrine concentration in coronary venous blood 
sampling, and regional myocardial blood flow (RMBF) were measured at times 
indicated by the closed circles.  The effect on reperfusion-induced arrhythmias was 
evaluated at 10-min after reperfusion.   
 
Figure 2: Percentage segment shortening (%SS) of the ischemic-reperfused area (% of 
baseline).  
Values are mean ± SEM. and represent all surviving pigs.  Group C (n=8): drug vehicle, 
group LD (n=8): low-dose dexmedetomidine (1 ng/mL), group MD (n=8): 
medium-dose dexmedetomidine (10 ng/mL), group HD (n=9): high-dose 
dexmedetomidine (100 ng/mL).  †: P < 0.05 vs. group C.  #: P < 0.05 vs. group LD.  




Figure 3: Plasma norepinephrine concentrations in coronary venous blood sampling of 
the ischemic-reperfused area.   
Values are mean ± SEM. and represent all surviving pigs.  Group C (n=8): drug vehicle, 
group LD (n=8): low-dose dexmedetomidine (1 ng/mL), group MD (n=8): 
medium-dose dexmedetomidine (10 ng/mL), group HD (n=9): high-dose 
dexmedetomidine (100 ng/mL).  *: P < 0.05 vs. baseline.  †: P < 0.05 vs. group C. 
 
Figure 4: Subendocardial to subepicardial (endo/epi) blood flow ratio in the 
ischemic-reperfused area.   
Values are mean ± SEM. and represent all surviving pigs.  Group C (n=8): drug vehicle, 
group LD (n=8): low-dose dexmedetomidine (1 ng/mL), group MD (n=8): 
medium-dose dexmedetomidine (10 ng/mL), group HD (n=9): high-dose 
dexmedetomidine (100 ng/mL).  *: P < 0.05 vs. baseline. 
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  Table 1: Assessments of reperfusion induced arrhythmias 
  Incidence of  Exclusions   Final Lidocaine  
   VT/VF (%) (Intractable VT/VF)  number   (mg/kg) 
Group C (n=12) 67  4   8 3.75 ± 0.41 
Group LD (n=9) 22  1   8 2.63 ± 0.63 †  
Group MD (n=9) 11†   1   8 2.13 ± 0.13 † 
Group HD (n=9) 11†   0   9 1.56 ± 0.41 † 
Values of lidocaine are mean ± SEM. and represent all surviving pigs.  VT = ventricular 
tachycardia; VF = ventricular fibrillation; Group C = drug vehicle; Group LD = low-dose 
dexmedetomidine (1 ng/mL); Group MD = medium-dose dexmedetomidine (10 ng/mL); 
Group HD = high-dose dexmedetomidine (100 ng/mL). 




Table 2: Hemodynamic Data 
       Reperfusion 
  Baseline  Pre-ischemia  Ischemia  5 min  30 min  60 min  90 min 
  (Pre-treatment) (Post-treatment) 
HR (beats/min) 
Group C (n=8) 89±4 89±4 88±5 94±5 95±6 92±7 91±5 
Group LD (n=8) 82±6 81±6 83±5 83±7 84±6 81±7 80±7 
Group MD (n=8) 87±5 85±4 81±4 84±4 86±4 87±4 88±3 
Group HD (n=9) 89±6 86±7 83±6 84±7 86±7 88±7 89±7 
LVPP (mmHg) 
Group C (n=8) 132±7 130±7 127±8 123±9 125±10 127±10 129±10 
Group LD (n=8) 129±8 129±7 124±7 125±9 126±8 129±8 134±8 
Group MD (n=8) 136±4 135±2 134±4 135±4 134±5 134±6 133±5 
Group HD (n=9) 140±5 140±4 134±5 133±4 138±4 138±4 140±4 
LVEDPmax (mmHg) 
Group C (n=8) 8.5±1.0 8.7±0.9 10.4±0.8* 9.8±1.1* 9.0±0.9 8.1±0.7 7.8±0.7 
Group LD (n=8) 9.1±1.0 9.3±1.1 10.6±1.1* 11.6±1.2* 9.3±1.0 8.9±0.9 8.8±0.8 
Group MD (n=8) 7.9±0.8 7.9±1.0 9.5±1.0* 9.2±1.1* 8.5±1.0 7.9±0.9 7.9±0.8 
Group HD (n=9) 8.6±0.8 8.7±0.7 10.2±1.0* 9.9±0.8* 8.9±0.5 8.5±0.8 8.2±0.7 
LVdP/dtmax (mmHg/s) 
Group C (n=8) 2908±161 2938±154 2360±151* 2288±184* 2414±182* 2431±174* 2520±186* 
Group LD (n=8) 2664±161 2572±168 2266±141* 2014±127* 2157±167* 2284±148* 2429±145* 
Group MD (n=8) 2915±145 2902±162 2416±148* 2410±137* 2612±173* 2781±194 2800±141 
Group HD (n=9) 3080±172 3054±169 2458±132* 2460±134* 2565±131* 2807±153 2965±165 
mCPP (mmHg) 
Group C (n=8) 121±7 121±6 117±8 114±9 116±9 116±9 119±9 
Group LD (n=8) 112±7 109±6 109±6 108±5 112±6 112±6 112±6 
Group MD (n=8) 124±4 122±4 122±4 121±3 122±4 122±5 121±5 
Group HD (n=9) 126±5 127±4 123±4 119±4 123±3 124±4 125±4 
CBF (ml/min) 
Group C (n=8) 22.2±3.2 22.4±3.4  35.4±4.0* 21.5±2.7 21.6±3.0 21.0±2.6 
Group LD (n=8) 24.8±1.8 24.6±2.1  39.1±3.6* 24.7±2.2 25.2±2.6 24.5±2.4 
Group MD (n=8) 21.4±2.8 21.7±3.2  38.7±4.5* 22.3±3.5 21.4±3.0 21.2±2.9 
Group HD (n=9) 20.3±2.0 20.1±2.3  32.9±2.8* 18.9±2.1 19.4±1.9 19.9±2.0 
%SS 
Group C (n=8) 22.0±2.2 21.9±2.2 -3.7±1.2* 6.5±1.1* 6.4±0.9* 6.9±0.8* 7.2±1.1* 
Group LD (n=8) 26.1±2.4 25.9±2.1 -2.7±1.0* 9.2±0.8* 11.7±0.9*† 13.4±1.1*† 15.1±1.2*† 
Group MD (n=8) 24.1±2.4 24.2±2.4 -3.8±0.8* 8.0±1.0* 11.1±1.0*† 13.0±1.0*† 14.6±1.2*† 
Group HD (n=9) 25.7±2.4 26.4±2.1 -4.3±0.7* 8.4±0.9* 12.5±1.5*† 15.1±1.7*† 18.4±1.6*† 
  
Values are mean ± SEM. and represent all surviving pigs.  HR = heart rate; LVPP = left 
ventricular peak pressure; LVEDP = left ventricular end-diastolic pressure; LVdp/dt = rate of 
increase of left ventricular pressure; mCPP = mean coronary perfusion pressure; CBF = 
coronary blood flow; %SS = percentage of segment shortening; Group C = drug vehicle; 
Group LD = low-dose dexmedetomidine (1 ng/mL); Group MD = medium-dose 
dexmedetomidine (10 ng/mL); Group HD = high-dose dexmedetomidine (100 ng/mL). 
*: Significantly different from baseline (p < 0.05).  †: significantly different from the 
corresponding value in group C (p < 0.05). 
